Stock DUL ALNYLAM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Market Closed - Börse Stuttgart
Other stock markets
 15:14:12 28/06/2024 BST 		5-day change 1st Jan Change
227.6 EUR -1.47% Intraday chart for Alnylam Pharmaceuticals, Inc. +55.68% +29.61%
06-28 UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
06-27 Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing
Sector Update: Health Care Stocks Ease Late Afternoon
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Top Midday Gainers
Los resultados del fármaco de Alnylam Pharmaceutical se consideran el "mejor escenario posible" -- Market Talk
Alnylam Pharmaceuticals Says Heart Disease Therapy Meets Primary Endpoint in Late-Stage Study
Alnylam's heart disease drug meets main goal in late-stage study
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Sector Update: Health Care
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. DUL Stock
  5. News Alnylam Pharmaceuticals, Inc.
  6. Other languages